逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
About Us
Company Profile
Business Model
Board of Directors
Management Team
Scientific Advisory Board
Others
R & D
Pipeline Overview
SIF Pipeline
FP-001：Prostate Cancer; Central Precocious Puberty
FP-014：Prostate Cancer
FP-016：Neurology/Psychiatry
FP-004：Opioid Dependence/Pain
FP-011：Breast Cancer
Other Research Projects
NCE Pipeline
FP-025：Asthma; COPD/ILD
FP-045: Fanconi Anemia; Pulmonary hypertension associated with interstitial lung disease (PH-ILD); Cardiovascular, Renal and Metabolism (CVRM); Peripheral artery disease (PAD)
FP-020: Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema
FP-040: CNS Diseases
Media
Press Release
Media Library
Investors
Corporate Governance
Corporate Charters
Board of Directors
Others
Material Information
News & Events
Press Releases
Events & Presentations
Financial Information
Financial Results
Monthly Revenues
Sharholder Information
Annual General Meeting
Major Shareholders
FAQs
Investor Contacts
Others
Career
Benefits
Join Us
Contact Us
繁體中文
HOME
繁體中文
HOME
Investors
Investor Contacts
Investor Contacts
Kana Huang
Investor Relations | Public Relations
+886-2-7750-0188
[email protected]
